Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study.

CONCLUSIONS: Ranibizumab intravitreal injections did not increase the overall risk of stroke or AMI. Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully. PMID: 32522792 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32522792?dopt=Abstract

Source: The British Journal of Ophthalmology - June 9, 2020 Category: Opthalmology Authors: Jeon HL, Byun SJ, Pratt NL, Sultana J, Park SJ, Shin JY Tags: Br J Ophthalmol Source Type: research